Sustainability Day March 24, 2026 Forward-Looking Statements Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to: | Forward-looking statements: | This presentation contains forward-looking statements regarding the Company's future plans, strategies, and pe ...

Financial Performance - Zai Lab Limited reported revenue of $106.49 million for the quarter ended March 2025, reflecting a year-over-year increase of 22.2% [1] - The earnings per share (EPS) for the quarter was -$0.45, an improvement from -$0.55 in the same quarter last year [1] - The reported revenue was below the Zacks Consensus Estimate of $117.09 million by 9.06% [1] - The EPS exceeded the consensus estimate of -$0.50 by 10.00% [1] Key Metrics - Product revenue for ZEJULA was $49.53 million, surpassing the average estimate of $48.32 million from three analysts [4] - Product revenue for OPTUNE reached $11.36 million, exceeding the average estimate of $8.35 million [4] - Product revenue for VYVGART was $18.11 million, falling short of the average estimate of $31.75 million [4] - Product revenue for NUZYRA was $15.12 million, slightly above the average estimate of $14.39 million [4] - Product revenue for QINLOCK was $8.51 million, exceeding the average estimate of $8.21 million [4] Stock Performance - Shares of Zai Lab Limited have returned +4.8% over the past month, compared to the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Financial Performance & Guidance - Zai Lab reported total revenue of $399.0 million for FY'24, a 50% year-over-year increase, and $109.1 million for 4Q'24, a 66% year-over-year increase[33, 34] - Adjusted loss from operations improved by 28% year-over-year for FY'24 and 53% year-over-year for 4Q'24[8] - The company's cash position was strong at $879.7 million as of December 31, 2024, compared to $806.5 million as of December 31, 2023[8, 46] - Zai Lab projects total revenue guidance of $560~$590 million for 2025 and targets profitability by 4Q'25[45] Product Performance & Pipeline - VYVGART/VYVGART Hytrulo revenue reached $93.6 million in FY'24, an 835% increase year-over-year, and $30.0 million in 4Q'24, a 492% increase year-over-year[33] - ZEJULA revenue was $187.1 million in FY'24, an 11% increase year-over-year, and $48.4 million in 4Q'24, a 16% increase year-over-year[33] - NUZYRA revenue was $43.2 million in FY'24, a 99% increase year-over-year, and $11.0 million in 4Q'24, an 81% increase year-over-year[33] - The company anticipates launching three new potential blockbuster drugs in China in 2025-26: Bemarituzumab, KarXT, and TTFields[13, 15, 17] Clinical Development & Regulatory Milestones - KarXT's NDA was accepted by the NMPA in January 2025 for schizophrenia[7, 16, 99] - ZL-1310 (DLL3 ADC) showed a 74% ORR in 2L+ SCLC patients in Phase 1 trials and was granted Orphan Drug Designation by the FDA for SCLC in Jan'25[8, 21, 22, 150] - The company plans to initiate a pivotal study for ZL-1310 in SCLC and a Phase 1 study in other DLL3-expressing tumors in 2025[26]